THALES
29.4.2021 10:02:07 CEST | Business Wire | Press release
To guarantee security and complete control of data, Thales and OVHcloud have joined forces to offer Citadel Team encrypted messaging customers a trusted hosting platform that guarantees the sovereignty of their data. Citadel Team customers' data is encrypted and stored at OVHcloud, via its own datacenters located in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005027/en/
Cybercriminals are taking advantage of the Covid-19 pandemic to infiltrate enterprise networks through vulnerabilities created by the large numbers of people working from home. With the sharp rise in cyberattacks — there have been four times the number of attacks in 2020 than in 2019 according to ANSSI , France’s national agency for information system security. There has also been a growing demand for greater security on data sharing and communication apps; it is more important than ever for companies and users to protect their information, encrypt their data and suitable hosting solution to control how it is stored.
Thales offers professionals a secure instant messaging service, Citadel Team, which requires users to register with a company email address. Already adopted by over a third of CAC 40 companies, the service includes the encryption system used by 50 NATO countries. It provides the guarantee that a company’s data will not be used or sold to third parties. It also ensures that all data is stored in France and that the organization can easily manage user devices themselves. Based on these guarantees, the Citadel development teams have recently obtained the France Cybersecurity 2021 label *.
Citadel Team’s new partner, OVHcloud, shares the same values ofsecurity, sovereignty and data protection. Hosting Citadel Team data in OVHcloud's data centers in France is a guarantee for customers of the application to benefit from an environment of trust. OVHcloud relies on an integrated model that gives it complete control over its value chain: from the design of its servers to the construction and management of its data centers, not forgetting the orchestration of its fiber optic network.
Available free of charge, Citadel Team offers users end-to-end encrypted messaging and voice services on a smartphone or computer, plus a host of premium services, including videoconferencing, group calls and screen sharing. Citadel Team continues to add new functionality tailored to the communication requirements of professionals to offer an all-in-one communication solution without sacrificing data security or usability. Citadel Team is also a member of the Open Trusted Cloud programme, initiated by OVHcloud to federate an ecosystem of trusted players and solutions that respect data protection laws.
“We are especially proud to announce this partnership to our customers and the general public. Thales and OVH have been trusted partners for many years, and by combining our strengths under this new hosting arrangement, we are taking the sovereign Citadel Team solution to the next level to offer our customers the very best data hosting option available.” Pierre-Yves Jolivet, Vice President, Cyber Defence Solutions, Thales.
« We welcome Thales' choice to host Citadel Team data on OVHcloud infrastructures. The combination of our strengths is good news for users looking for guarantees that their data will be respected. They can now be sure to benefit from an alternative, trusted and secure end-to-end solution.» Caroline Comet-Fraigneau, VP France and Benelux, OVHcloud
* The label «France Cybersecurity », is a guarantee for users that the products and services bearing the label are French and that they have clear and well-defined functionalities, with a level of quality attested by an independent jury.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Defence and Security | Thales Group
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
